(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of 18.19% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 31.15%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.98%.
Ptc Therapeutics's revenue in 2026 is $1,008,754,000.On average, 18 Wall Street analysts forecast PTCT's revenue for 2026 to be $107,414,052,174, with the lowest PTCT revenue forecast at $97,649,138,340, and the highest PTCT revenue forecast at $116,177,436,384. On average, 18 Wall Street analysts forecast PTCT's revenue for 2027 to be $120,100,094,078, with the lowest PTCT revenue forecast at $82,898,276,195, and the highest PTCT revenue forecast at $167,589,290,416.
In 2028, PTCT is forecast to generate $140,381,068,964 in revenue, with the lowest revenue forecast at $90,972,274,180 and the highest revenue forecast at $205,146,651,316.